Poractant alfa
| Clinical data | |
|---|---|
| Trade names | Curosurf |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration |
endotracheal |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Poractant alfa is a pulmonary surfactant sold under the brand name Curosurf by Chiesi Farmaceutici. Poractant alfa is an extract of natural porcine lung surfactant. As with other surfactants, marked improvement on oxygenation may occur within minutes of the administration of poractant alfa.
Each milliliter of poractant alfa contains 80 mg of surfactant (extract) that includes 76 mg of phospholipids and 1 mg of protein of which 0.2 mg is surfactant protein B (SP-B). Depending on local country registration, CUROSURF is available in 1.5mL vials, 3.0mL vials, and/or twin packs containing two 1.5mL vials.
The amount of phospholipids is calculated from the content of phosphorus and contains 55 mg of phosphotidylcholine of which 30 mg is dipalmitoylphosphatidylcholine.
Transient episodes of bradycardia, decreased oxygen saturation, hypotension, or endotracheal tube blockage may occur.
Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during mechanical ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures.
A deficiency of pulmonary surfactant in preterm infants results in respiratory distress syndrome. Poractant alfa compensates for the surfactant deficiency and restores surface activity to the lung tissue.
As with other surfactants, marked improvements in oxygenation may occur within minutes of the administration of Curosurf.
...
Wikipedia